Search results
Results From The WOW.Com Content Network
Tiludronic acid (INN; also known as tiludronate) is a bisphosphonate used for treatment of Paget's disease of bone (osteitis deformans) in human being medicine. It has the tradename Skelid. In veterinary medicine, tiludronic acid is used to treat navicular disease and bone spavin in horses. Its tradenames are Tildren and Equidronate.
Mueller–Weiss syndrome, also known as Mueller–Weiss disease, is a rare [2] idiopathic degenerative disease of the adult navicular bone characterized by progressive collapse and fragmentation, leading to mid- and hindfoot pain and deformity. [3] [1] It is most commonly seen in females, ages 40–60. [4]
Navicular disease or navicular syndrome: a catch-all phrase used to describe pain in the palmar hoof which was originally attributed to damage to the navicular bone. MRI has since shown that navicular syndrome may be caused by damage to any of the structures within the hoof, including the navicular bone, the navicular bursa, the coffin joint ...
Navicular syndrome, often called navicular disease, is a syndrome of lameness problems in horses. It most commonly describes an inflammation or degeneration of the navicular bone and its surrounding tissues, usually on the front feet. It can lead to significant and even disabling lameness. [1]
Köhler disease (also spelled "Kohler" and referred to in some texts as Kohler disease I) [1] is a rare bone disorder of the foot found in children between six and nine years of age. The disease typically affects boys, but it can also affect girls. It was first described in 1908 by Alban Köhler (1874–1947), a German radiologist.
Taking precautions to protect yourself from a quartet of infectious diseases can lessen your odds of starting off 2025 sick. Public health experts are warning of a ‘quad-demic’ this winter.
RICE is a mnemonic acronym for the four elements of a treatment regimen that was once recommended for soft tissue injuries: rest, ice, compression, and elevation. [1] It was considered a first-aid treatment rather than a cure and aimed to control inflammation. [2]
Currently, there are 18 mutations and conditions in the Cure Rare Disease pipeline, including Duchenne muscular dystrophy, various subtypes of Limb-girdle muscular dystrophy, spinocerebellar ataxia type 3 (SCA3), and ADSSL1 distal myopathy. As of 2022, none of these conditions have a viable treatment available for the population impacted.